State Street SPDR S&P Pharmaceuticals ETF
XPH
79 hedge funds and large institutions have $112M invested in State Street SPDR S&P Pharmaceuticals ETF in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 25 reducing their positions, and 13 closing their positions.
2% less funds holding
Funds holding: 81 → 79 (-2)
5.98% less ownership
Funds ownership: 47.65% → 41.66% (-6%)
12% less capital invested
Capital invested by funds: $127M → $112M (-$14.9M)
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
28% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$5.05M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$5.04M |
| 3 |
CI
CX Institutional
Auburn,
Indiana
|
+$2.15M |
| 4 |
FCM
Fortis Capital Management
Bellevue,
Washington
|
+$2.01M |
| 5 |
CF
Centaurus Financial
Anaheim,
California
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FMI
Factory Mutual Insurance
Waltham,
Massachusetts
|
-$10.6M |
| 2 |
Goldman Sachs
New York
|
-$10.4M |
| 3 |
Morgan Stanley
New York
|
-$3.35M |
| 4 |
JP Morgan Chase
New York
|
-$2.58M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.76M |
XPH Hedge Fund Activity: Q2 2021 in Review
79 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2021, worth a combined $112M — down 12% from $127M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of XPH and 11 opened new positions — a net loss of 2 holders — while 25 trimmed existing stakes and 18 added.
The largest buyer was Bank of America, adding an estimated $5.05M. The largest seller was Factory Mutual Insurance, exiting entirely with an estimated $10.6M sold.
- 79 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2021, down from 81 in Q1 2021.
- Funds reported $112M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2021, down 12% quarter-over-quarter.
- 11 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2021 and 13 closed out, a net change of -2 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2021 was Bank of America, an estimated $5.05M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2021 was Factory Mutual Insurance, an estimated $10.6M sold.
Based on aggregated 13F filings for Q2 2021.